Cagrilintide for weight loss: what week 4 won't tell you

What did @kristinastout actually say?

In short: a nurse practitioner documented her personal four-week experiment stopping her GLP-1 maintenance dose to run cagrilintide alone, found the appetite suppression underwhelming, then added her GLP-1 back and reported dramatic results. Her words: "I just could not bring myself to eat" and she "completely forgot to eat" for an entire day. She's selling a four-month supply for $450 through her own clinic.

She also frames this as evidence that cagrilintide is "definitely working" and positions the combination as a solution for patients who want more appetite suppression on top of their existing GLP-1 therapy. That's a lot of clinical weight to put on a single-person, no-control, self-reported experiment from someone who has a direct financial interest in the product she's describing.

Does the science back this up?

Partially, but the mechanism she's describing is real, even if her self-experiment isn't evidence of anything. Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk. The combination of cagrilintide with semaglutide, studied under the name CagriSema, has shown meaningful results in clinical trials.

Enebo et al. (2021, The Lancet) published Phase 1b/2a data showing cagrilintide plus semaglutide produced greater weight loss than either agent alone in adults with obesity, with the combination achieving up to 17.1% body weight reduction over 32 weeks. The REDEFINE 1 trial (presented at ENDO 2024) showed CagriSema achieved roughly 22.7% weight loss at 68 weeks in non-diabetic adults with obesity, outperforming semaglutide alone. So the idea that adding an amylin agonist to a GLP-1 receptor agonist produces stronger appetite suppression than either drug alone is supported by actual trial data.

What is not supported is using her personal experience as clinical guidance for patients.

What did they get wrong (or right)?

She got the basic pharmacology directionally right. Amylin and GLP-1 work through different but complementary pathways, and combining them does appear to produce additive appetite suppression in controlled settings. Credit where it's due.

What she got wrong is the epistemology. Forgetting to eat once during week four of a self-experiment tells us nothing about whether cagrilintide caused it, whether the dose escalation timing coincided with something else, or whether this would generalize to her patients. She also attributes the effect to cagrilintide specifically, but she added her GLP-1 back at the same time. The variable she changed was re-adding the GLP-1, not escalating cagrilintide. Her own timeline undermines her conclusion.

The promotional close, directing viewers to book a consultation at her clinic where she sells the product she just reviewed, is a conflict of interest that should have been disclosed up front and clearly labeled as advertising. It wasn't.

What should you actually know?

Cagrilintide is not FDA-approved as a standalone drug in the United States as of mid-2025. CagriSema (the fixed-ratio combination) is in Phase 3 trials. What's being sold through clinics like the one she's promoting is compounded cagrilintide, which is not the same as the investigational drug used in Novo Nordisk's trials. Compounded versions have not been evaluated for purity, bioavailability, or safety in the same way.

The side effect profile of the combination in trials includes nausea, vomiting, and injection site reactions. More importantly, the "I forgot to eat all day" experience she describes approvingly can reflect a degree of appetite suppression that, if it persists or intensifies at higher doses, carries real risks, including inadequate protein intake, micronutrient deficiency, and disordered eating patterns. A clinician framing forgetting to eat as a positive outcome, without any discussion of nutritional monitoring, is worth flagging.

If you're interested in this class of drugs, talk to a physician who isn't selling the product they're recommending.

Is the pricing she cited reasonable or a red flag?

The $450 for a four-month supply figure she cites is on the lower end of what compounding pharmacies charge for cagrilintide, but pricing for compounded peptides varies enormously and is not regulated. There's no public benchmark for what "fair" looks like here. What matters more is whether the prescribing clinician has done a proper intake, reviewed contraindications, and will provide follow-up monitoring. A price point tells you almost nothing about the quality or safety of the product or the care surrounding it.